Terns Pharmaceuticals Inc... (TERN)
Terns Pharmaceuticals Statistics
Share Statistics
Terns Pharmaceuticals has 87.3M shares outstanding. The number of shares has increased by 34.97% in one year.
| Shares Outstanding | 87.3M |
| Shares Change (YoY) | 34.97% |
| Shares Change (QoQ) | 2.78% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 65.3M |
| Failed to Deliver (FTD) Shares | 22.95K |
| FTD / Avg. Volume | 1.73% |
Short Selling Information
The latest short interest is 5.77M, so 6.6% of the outstanding shares have been sold short.
| Short Interest | 5.77M |
| Short % of Shares Out | 6.6% |
| Short % of Float | 7.24% |
| Short Ratio (days to cover) | 6.73 |
Valuation Ratios
The PE ratio is -4.96 and the forward PE ratio is -2.22. Terns Pharmaceuticals's PEG ratio is 0.42.
| PE Ratio | -4.96 |
| Forward PE | -2.22 |
| PS Ratio | 0 |
| Forward PS | 37.6 |
| PB Ratio | 1.27 |
| P/FCF Ratio | -6.29 |
| PEG Ratio | 0.42 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Terns Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 23.14, with a Debt / Equity ratio of 0.
| Current Ratio | 23.14 |
| Quick Ratio | 23.14 |
| Debt / Equity | 0 |
| Debt / EBITDA | -0.01 |
| Debt / FCF | -0.02 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-1.51M |
| Employee Count | 59 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -260K |
| Effective Tax Rate | 0.29% |
Stock Price Statistics
The stock price has increased by -40.53% in the last 52 weeks. The beta is -0.14, so Terns Pharmaceuticals's price volatility has been lower than the market average.
| Beta | -0.14 |
| 52-Week Price Change | -40.53% |
| 50-Day Moving Average | 3.13 |
| 200-Day Moving Average | 6.03 |
| Relative Strength Index (RSI) | 54.13 |
| Average Volume (20 Days) | 1.33M |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -101.87M |
| Net Income | -88.85M |
| EBITDA | -101.87M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -1.12 |
Balance Sheet
The company has 161.44M in cash and 1.35M in debt, giving a net cash position of 160.09M.
| Cash & Cash Equivalents | 161.44M |
| Total Debt | 1.35M |
| Net Cash | 160.09M |
| Retained Earnings | -421.48M |
| Total Assets | 363.93M |
| Working Capital | 346.46M |
Cash Flow
In the last 12 months, operating cash flow was -70.02M and capital expenditures -42K, giving a free cash flow of -70.06M.
| Operating Cash Flow | -70.02M |
| Capital Expenditures | -42K |
| Free Cash Flow | -70.06M |
| FCF Per Share | -0.88 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TERN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for TERN is $20, which is 584.9% higher than the current price. The consensus rating is "Buy".
| Price Target | $20 |
| Price Target Difference | 584.9% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Scores
| Altman Z-Score | 6.95 |
| Piotroski F-Score | 2 |